NEW YORK, June 16, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Clovis Oncology, Inc. (NASDAQ: CLVS), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Techne Corp. (NASDAQ: TECH) and Repligen Corporation (NASDAQ: REGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3298-100free.
--
Cubist Pharmaceuticals Inc. Analyst Notes
On June 12, 2014, Cubist Pharmaceuticals Inc. (Cubist) stock declined slightly by 0.76% to end the day at $69.41. The Company's stock increased 1.06% over the past five trading days compared to the Nasdaq Composite which rose 0.03% during the same trading period. The full analyst notes on Cubist are available to download free of charge at:
http://www.analystsreview.com/Jun-16-2014/CBST/report.pdf
--
Clovis Oncology, Inc. Analyst Notes
On May 31, 2014, Clovis Oncology, Inc. (Clovis) announced the final Phase 1 as well as preliminary Phase 2 results from an ongoing Phase 1/2 monotherapy study of Rucaparib. Rucaparib is the Company's investigational oral, potent, small molecule inhibitor of PARP1 and PARP2, which is being developed for the maintenance treatment of platinum-sensitive ovarian cancer in patients with homologous recombination deficient (HRD) tumors. "These data demonstrate rucaparib's very encouraging clinical efficacy and tolerability profile in patients with solid tumors, which is now being explored in the ARIEL program in patients with ovarian cancer as well as the RucaPanc study in pancreatic cancer patients, each of which represents an area of significant unmet need," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. The full analyst notes on Clovis are available to download free of charge at:
http://www.analystsreview.com/Jun-16-2014/CLVS/report.pdf
--
Ligand Pharmaceuticals Incorporated Analyst Notes
On May 12, 2014, Ligand Pharmaceuticals Inc. (Ligand) announced that it has earned a milestone payment totaling $150,000 from SAGE Therapeutics. The Company informed that the milestone was in connection to a previous commencement by SAGE of a Phase 1/2 clinical trial of SAGE-547 for the treatment of super-refractory status epilepticus (SRSE). SRSE is a life-threatening seizure condition in which the brain is in a state of persistent seizure. John Higgins, President and CEO of Ligand said, "The treatment options for status epilepticus, a life-threatening disease, are inherently limited and there are no specifically approved therapies for SRSE. Our partnership with SAGE is but one example of Ligand's science and technologies being utilized under licensing agreements to develop or improve treatments across a variety of medical conditions." The full analyst notes on Ligand are available to download free of charge at:
http://www.analystsreview.com/Jun-16-2014/LGND/report.pdf
--
Techne Corp. Analyst Notes
On May 15, 2014, Techne Corp. (Bio-Techne) announced that Harold Wiens, a 30+ year veteran of 3M company, has joined Bio-Techne's Board of Directors. According to the Company, his appointment brings additional seasoned global business experience to an already well-established team. Bio-Techne President and CEO, Chuck Kummeth said, "Harold brings amazing attributes and experiences to our board at a critical time as we expand the company globally and drive customer focus and innovation. Harold is deeply knowledgeable in international business practices and, as we drive growth and more innovation here at Bio-Techne, he will be instrumental in guiding balance between operations and accelerated growth." The full analyst notes on Bio-Techne are available to download free of charge at:
http://www.analystsreview.com/Jun-16-2014/TECH/report.pdf
--
Repligen Corporation Analyst Notes
On May 6, 2014, Repligen Corp. (Repligen) announced that Tony J. Hunt has been appointed to the Company's newly created position of Chief Operating Officer. "We welcome Tony to the Repligen management team, where his industry knowledge and understanding of bioproduction market drivers will help guide the expansion of our commercial operations," said Walter C. Herlihy, Ph.D., President and CEO of Repligen. "The expertise that Tony brings is particularly well aligned to Repligen's needs as we pursue multiple opportunities to grow our bioprocessing business." Mr. Hunt most recently served as the President, BioProduction at Life Technologies, where he played a key role in the development and growth of the company's bioprocessing business. The full analyst notes on Repligen are available to download free of charge at:
http://www.analystsreview.com/Jun-16-2014/REGN/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
